ACTRN12609000571279CompletedPhase 3
Prospective non controlled study of immunogenicity of Human Papilloma Virus (HPV) Vaccine in groups at special risk of poor vaccine result
ational Health and Medical Research Council & Clinical Centre of Research Excellence(NHMRC CCRE) in Childhood and Adolescent Immunisation0 sites100 target enrollmentStarted: July 13, 2009Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Non-randomised trial
- Primary Purpose
- Prevention
- Masking
- Open (masking not used)
Eligibility Criteria
- Ages
- 12 Years to 26 Years (—)
- Sex
- Female
Inclusion Criteria
- •Females aged 12-26 years
- •Have been diagnosed by a specialist with one of the six chronic medical conditions described.
- •Special Risk Groups
- •1. Paediatric Rheumatalogical Disease
- •2. Inflammatory Bowel Disease
- •3. Acute Lymphoblastic Leukaemia
- •4. Solid Organ Transplant Recipients (kidney and liver)
- •5. Chronic Renal Disease
- •6. Bone Marrow Transsplant
Exclusion Criteria
- •Previous immunisation with HPV vaccine
- •Recognised contraindication to the receipt of the vaccine e.g. anaphylaxis
Investigators
Similar Trials
Completed
Phase 1
A study to evaluate the immunogenicity and safety of smallpox vaccine as vaccination to monkeypox in healthy adultsMonkeypoxJPRN-jRCTs031220171jiie Mugen50
Completed
Not Applicable
Brief intervention in substance use disorders: pilot studyIRCT201209301958N3Office of Psychosocial Health and Addiction, Ministry of Health30
Not yet recruiting
Phase 1
Probiotics to initiate ovulation in women with PolyCystic Ovarian Syndrome (PCOS) and Irritable Bowel Syndrome (IBS)ACTRN12612001192875niversity of South Australia16
Recruiting
Not Applicable
A prospective, controlled, clinical study to evaluate the impact of UV-irradiation on the electrical impedance spectroscopy scores of neviQ82.5Congenital non-neoplastic naevusDRKS00012456niversitätsklinikum Heidelberg50
Completed
Not Applicable
Prospective, non-interventional, open-label study on the prophylactic use of a pegylated filgrastim (Pelgraz®) to reduce the duration of neutropenia and the incidence of febrile neutropenia under conventional chemotherapy for the treatment of haematological malignancies and solid tumorsfebrile neutropeniaD70.0DRKS00017218ACCORD Healthcare GmbH1,665